Corticosteroid ODT Composition for Low-Dose Blend Uniformity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for eosinophilic esophagitis, such as systemic corticosteroids and topical inhalers, are associated with significant adverse effects and challenges in achieving blend uniformity and content uniformity of low-dose corticosteroid compositions, leading to inconsistent therapeutic outcomes.
Innovation Solution
A low-dose, topically acting corticosteroid composition adsorbed onto a pharmaceutically acceptable carrier like silicified microcrystalline cellulose, formulated as an orally disintegrating tablet (ODT) to ensure blend and content uniformity, minimizing systemic absorption and maximizing topical efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic corticosteroids are used to treat eosinophilic esophagitis, then therapeutic efficacy is improved, but systemic side effects such as HPA axis suppression and growth retardation increase
Solution Approach 1:
The patent applies local quality by formulating corticosteroids in an orally disintegrating tablet that releases the drug topically in the oral cavity and esophagus, rather than systemically. The composition is designed to act locally at the site of inflammation (eosinophilic esophagitis) while minimizing systemic absorption, thereby maintaining therapeutic efficacy at the target site while reducing systemic side effects like HPA axis suppression and growth retardation.
Solution Approach 2:
The patent uses an orally disintegrating tablet formulation as an intermediary vehicle that delivers corticosteroids topically. The ODT acts as a mediator between the drug and the target tissue, enabling localized delivery through dissolution in the oral cavity and subsequent topical action on the esophageal mucosa, thus avoiding direct systemic circulation of the corticosteroid.
2Object-affected harmful factors
If low-dose corticosteroid compositions are formulated, then systemic side effects are reduced, but blend uniformity and content uniformity become difficult to achieve
Solution Approach 1:
The patent employs composite materials by incorporating corticosteroids into an orally disintegrating tablet matrix composed of multiple excipients including disintegrants, binders, and fillers. This composite formulation approach allows the low-dose corticosteroid to be uniformly distributed throughout the tablet matrix, achieving both blend uniformity and content uniformity while maintaining the low dose necessary to minimize systemic side effects.
Solution Approach 2:
The patent applies parameter changes by optimizing the physical and chemical parameters of the ODT formulation, including particle size distribution, porosity, and dissolution rate. These parameter optimizations ensure uniform distribution of low-dose corticosteroids throughout the tablet, achieving the required blend and content uniformity despite the low drug load, while the rapid disintegration ensures consistent topical delivery.
3Reliability
If orally disintegrating tablet formulation is used, then topical delivery to esophageal tissues is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the tablet into functional components with specific roles: disintegrant segments that rapidly break down the tablet structure, binder segments that hold the composition together, and corticosteroid segments that provide therapeutic action. This segmentation of functions within the ODT formulation enables optimized topical delivery while using standard manufacturing processes for each component, thereby managing manufacturing complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ODT formulation provides rapid disintegration and uniform distribution of corticosteroids to inflamed esophageal tissues, effectively treating eosinophilic esophagitis with minimal systemic side effects.
Implementation Method 1
A low-dose, topically acting corticosteroid composition adsorbed onto a pharmaceutically acceptable carrier like silicified microcrystalline cellulose
Data Source
AI summary
The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.